×

Nexvet Hosting Teleconference to Provide Update on NV-01 Pivotal Study

DUBLIN, Ireland, Nov. 14, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, will host a conference call on Monday, November 16th, 2015 at 9:00 AM Eastern Time to provide an update on the Company's pivotal safety and efficacy study for NV-01, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain associated with osteoarthritis in dogs. The Company plans to issue a press release regarding the study prior to the teleconference.

To access the live webcast, please visit the Investor Relations page of the Nexvet website at http://ir.nexvet.com/. Alternatively, participants may access the live conference call by dialing (877) 303-1599 (US) or (440) 996-5696 (international) and using conference ID 82527564. An audio archive of the webcast will be available following the call at http://ir.nexvet.com/.

About Nexvet (www.nexvet.com)

Nexvet is a veterinary biologics developer focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet's proprietary PETization™ platform is designed to rapidly design mAbs that are recognized as "self" or "native" by an animal's immune system, a property Nexvet refers to as "100% species-specificity." Nexvet's product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.

Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, through conducting drug discovery in Australia, clinical development in the United States and Europe and biomanufacturing in Ireland.

CONTACT: Further information: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 4 cknoll@bplifescience.com Media David Salisbury Berry & Company Public Relations +1 212-253-8881 dsalisbury@berrypr.com

Source:Nexvet Biopharma plc